Pfizer was warned of Lyme study problems months ago, trial research startup's CEO tells employees
A contract research startup working on Pfizer’s Lyme vaccine trial alerted the drugmaker to problems with the study last year, but was told to keep the work moving to avoid raising public concerns about vaccine safety, the startup’s CEO has privately told employees in recent days.
Up until last week, Reify Health’s trials business, Care Access, was running more than half the US sites for Pfizer’s final-stage Lyme trial, and had enrolled thousands of people. In the days since Pfizer yanked the richly valued startup off the work, Reify CEO Ralph Passarella has told employees that his company months ago asked to pause its portion of the trial while it investigated issues.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.